🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

102 results for “GlaxoSmithKline Biologicals S.A.” Clear

  1. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B

    phase 2 small molecule active

    1 trial

  2. Reblozyl 75 mg powder for solution for injection

    GlaxoSmithKline Biologicals S.A.

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  3. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline Biologicals S.A.

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  4. Zejula 100 mg film-coated tablets, Zejula 100 mg film-coated tablets

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 2 small molecule active

    1 trial

  5. sterile saline solution (0.9% w/v solution of NaCl in water).

    GlaxoSmithKline Biologicals S.A.

    Urinary Tract Infections

    phase 2 small molecule active

    1 trial

  6. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 1 other active

    1 trial

  7. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 1 other active

    1 trial

  8. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 1 other active

    1 trial

  9. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

    GlaxoSmithKline Biologicals S.A.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  10. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  11. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline Biologicals S.A.

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  12. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline Biologicals S.A.

    Multiple Myeloma

    phase 1 other active

    1 trial

  13. A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease

    GlaxoSmithKline Biologicals S.A.

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  14. A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  15. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline Biologicals S.A.

    Healthy volunteers

    phase 1 other active

    1 trial

  16. A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.

    GlaxoSmithKline Biologicals S.A.

    Mild Asthma

    phase 1 other active

    1 trial

  17. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline Biologicals S.A.

    Kidney Disease

    phase 1 other active

    1 trial

  18. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline Biologicals S.A.

    Tuberculosis

    phase 1 other active

    1 trial

  19. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline Biologicals S.A.

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  20. A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

    GlaxoSmithKline Biologicals S.A.

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  21. A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

    GlaxoSmithKline Biologicals S.A.

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  22. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline Biologicals S.A.

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  23. First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

    GlaxoSmithKline Biologicals S.A.

    Neoplasms

    phase 1 other active

    1 trial

  24. Phase 1, Open-Label, single arm (Non-comparator) Study to Evaluate the Pharmacokinetics and Safety of a Single Dose of Oral Gepotidacin in Addition to Antibacterial Standard of Care in Pediatric Participants from 2 to less than 12 years of age with a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis with Antibiotics

    GlaxoSmithKline Biologicals S.A.

    Urinary Tract Infections

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources